Article
Study Compares Triple, Dual Therapies for COPD
Author(s):
A new study comparing triple therapy for chronic obstructive pulmonary disease (COPD) against dual therapy resulted in a lower rate of moderate or severe COPD exacerbations and a lower rate of hospitalizations.
A new study comparing triple therapy for chronic obstructive pulmonary disease (COPD) against dual therapy resulted in a lower rate of moderate or severe COPD exacerbations and a lower rate of hospitalizations. However, triple therapy had a much higher incidence of pneumonia, which the researchers said was to be expected.
Triple inhaled therapy for COPD consists of a combined inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). Triple therapy is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for patients who experience recurrent exacerbations despite treatment with either a dual bronchodilator or LABA/ICS combination. The GOLD guidelines do not recommend ICS as a monotherapy given the pneumonia risks.
Results of the study—The Informing the Pathway of COPD Treatment (IMPACT) trial—were published in The New England Journal of Medicine Wednesday.1 The 1-year randomized trial involved 10,355 patients with COPD.
Click to continue reading on The American Journal of Managed Care.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
